The treatment landscape for atopic dermatitis (AD) in the United States is undergoing a revolution. Since 2017, six agents have been approved by the FDA (four of these since the start of 2021),…
First-line treatment of chronic heart failure (CHF) usually involves an angiotensin-converting enzyme (ACE) inhibitor, an oral beta blocker, or an oral diuretic. The addition of a second- or third-…
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder associated with progressive inflammation and/or fibrosis of the lung tissue. The leading cause of the disorder is unknown. Individuals…
The addition of immune checkpoint inhibitors to the renal cell carcinoma armamentarium has significantly changed the treatment of this disease. In 2021, Keytruda (Merck & Co.) became the first…
Key benefits and uses Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to position…
Disorders such as anxiety, substance use disorder, and insomnia frequently coexist with major depressive disorder (MDD) and present treatment challenges to psychiatrists and primary care…
Copy/Paste the core content from the latest edited report brochure. DELETE the “Market Outlook” header from the top. Venous thromboembolism (VTE) is the obstruction of a vein caused by a…
For more than a decade, AbbVie’s Restasis was the only FDA-approved therapy for dry eye disease (DED) until the launch of Novartis’s Xiidra in 2016, followed by Restasis MultiDose, Sun…
Vitiligo is a chronic skin depigmentation disorder characterized by the destruction or loss of function of melanocytes. Its etiology and pathophysiology are not well understood but are believed to…
Clarivate Epidemiology’s coverage of osteoporosis (OSP) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of OSP for each country…
Clarivate Epidemiology’s coverage of osteoporosis (OSP) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of OSP for each country…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key osteoporosis patient populations, covering 171 countries and more…
Clarivate Epidemiology’s coverage of osteoporosis (OSP) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of OSP for each country…
Clarivate Epidemiology’s coverage of dermatitis / eczema comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dermatitis / eczema…
Clarivate Epidemiology’s coverage of osteoporosis comprises epidemiological estimates of key patient populations in 45 countries worldwide. Most patient populations are forecast over a period of…